ArticleJournal of ophthalmology2019
Risk Factors for Persistent or Recurrent Central Serous Chorioretinopathy.
Article in Journal of ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Central Serous Chorioretinopathy and Personality Characteristics: A Systematic Review of Scientific Evidence over the Last 10 Years (2010 to 2020).Medicina (Kaunas, Lithuania) · 2021Pooled it
- Choroidal imaging biomarkers as predictors of recurrent central serous chorioretinopathy: A multicenter retrospective study - MICRoN report number five.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Longitudinal polarization diversity optical coherence tomography before and after photodynamic therapy in chronic central serous chorioretinopathy: a prospective clinical study.International journal of retina and vitreous · 2026Article
- Clinical and multimodal imaging characteristics of acute central serous chorioretinopathy with fibrinous exudation.International journal of ophthalmology · 2026Article
- Changes in Aqueous Concentrations of Various Cytokines after Intravitreal Bevacizumab Injection for Chronic Central Serous Chorioretinopathy.Korean journal of ophthalmology : KJO · 2023Article
- Functional Outcomes and Safety Profile of Trans-Foveal Subthreshold Micropulse Laser in Persistent Central Serous Chorioretinopathy.Life (Basel, Switzerland) · 2023Article
- Longitudinal follow-up and outcome analysis in central serous chorioretinopathy.Eye (London, England) · 2023Observational
- Diagnostic and Therapeutic Challenges in a Patient with Radiation Retinopathy Complicated by Corticosteroid-Induced Central Serous Chorioretinopathy.Medicina (Kaunas, Lithuania) · 2022Article
- Sharing the Same Perspective. Mental Disorders and Central Serous Chorioretinopathy: A Systematic Review of Evidence from 2010 to 2020.Biomedicines · 2021Review
- Central Serous Chorioretinopathy and Blood Serotonin Concentrations.Journal of clinical medicine · 2021Article
- Clinical Characteristics of Pregnancy-Associated Central Serous Chorioretinopathy in the Chinese Population.Journal of ophthalmology · 2021Article
- Predicting Central Serous Chorioretinopathy Recurrence Using Machine Learning.Frontiers in physiology · 2021Article
- Deep Learning for Detecting Subretinal Fluid and Discerning Macular Status by Fundus Images in Central Serous Chorioretinopathy.Frontiers in bioengineering and biotechnology · 2021Article
- Intravitreal linezolid in the management of vancomycin-resistant enterococcal endophthalmitis.American journal of ophthalmology case reports · 2020Article
- Central Serous Chorioretinopathy Risk Factors in An Iranian Cohort: A Case-control Study.Journal of ophthalmic & vision researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the risk factors for persistent or recurrent central serous chorioretinopathy (CSC). MATERIALS AND
methodsConsecutive treatment-naïve CSC patients were included from January 2017 to October 2018. All patients were asked to complete questionnaires, addressing previously described risk factors for the development of CSC. Patients were divided into two groups: those with acute CSC, who were in the first episode, with spontaneous resolution of subretinal fluid within 3 months, and with no recurrence within 1 year; and those with persistent or recurrent CSC, the remaining patients.
resultsIn total, 138 patients were enrolled: 20 (14.5%) with acute CSC and 118 (85.5%) with persistent or recurrent CSC. Using multivariate analysis, male sex (odds ratio (OR), 95% confidence interval: 5.63 [1.02-31.02];
conclusionsMale sex, age, and sleep disorders are risk factors for persistent or recurrent CSC in the natural history. These patients may require early photodynamic therapy. Treatment for sleep disorders is strongly recommended. All CSC patients may require careful and periodic follow-up.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.